NXRA Nextera Enterprises Inc. featured news, full reports, and detailed charts
Nextera Enterprises Inc. (NXRA/NXRA.PK) Wrap Up:
Nextera Enterprises, Inc., through its subsidiary, W Lab Acquisition Corp., develops and markets branded consumer products that offer solutions to niche personal care needs. It offers cosmetic remedies for spider veins, dark circles, blotchy skin, bruises, stretch marks, sun spots, at home microdermabrasion kit, and deep facial lines under the Vita-K Solution brand. The company, under the DermaFreeze365 brand, offers instant line relaxing formula as an anti-line and wrinkle cream for the face, neck and chest, and lip areas; and offers two anti-aging compounds: Gamma-Amino Butyric Acid, a new ingredient in modern skin care technology, and BioxiLift, which produces a cumulative reduction in the appearance of fine lines and wrinkles. It also offers Ellin LaVar Textures brand products to address the health and condition of hair and scalp, including OptiMoist Shampoo, SatinSoft Conditioner, LiquidGlass, PenetratingBalm, ReconstructMasque, ThermMist, NourishOil, DetangleMist, LiquidMotion, InstantShine, ScalpRx, and NaturalControl. In addition, Nextera Enterprises offers dry shampoo product in an aerosol spray formulation under the Psssssst brand; and a recipe for ageless skin under the Skin Appetit brand. It also markets its products at retail under the Heavy Duty, 40 Carrots, Virtual Laser, Stoppers-4, Bath Lounge, Vita-C2, Firminol-10, and TurboShave brands. The company markets its products to drug, food, and mass-merchandise retail chains through a team of internal sales managers, as well as a sales force of independent sales representatives. Its customers include chain drugstores, mass volume retailers, national mass merchandisers, and grocery chains. Nextera Enterprises, Inc. was founded in 1997 and is based in Panorama City, California.Nextera Enterprises Inc. (NXRA:OTC)
|
Market Cap
116.1K
|
Total Revenue
7.9M
|
|
|
EBITDA
3.3M
|
DILUTED EPS TTM
-0.37
|
|
|
P/E
--
|
P/S
0.0x
|
|
|
Return On Asset
-12.99
|
Return On Equity
-375.65
|
|
| K = Thousands M = Millions B = Billions | ||
related news
NXRA Top Compensated Officers
Executives, Board Directors
Key developments for Nextera Enterprises Inc. (NXRA)
Nextera Enterprises Inc has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Class A Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.
Nextera Enterprises Inc. filed its 10-K on May 14, 2008 for the period ending December 31, 2007. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Nextera Enterprises, Inc. has announced that it intends to deregister the Company’s common stock under Sections 12(g) and 15(d) of the Securities Exchange Act of 1934. As of January 31, 2008, the Company had less than 300 shareholders of record, and as a result has not been obligated to file annual, quarterly and current reports under the Exchange Act. In addition to freeing up significant internal resources, management estimates that the cessation of these reporting obligations will result in significant savings in legal, accounting, and administrative expenses and compliance related costs associated with Section 404 of the Sarbanes-Oxley Act. The Company’s President, Joe Millin, stated, “As our management team and board examined the relative advantages and disadvantages of our status as a public company, it became apparent that in view of our limited public float, the relative illiquidity of our stock and our current financial condition, the compliance costs involved in maintaining that status outweighed the potential benefits of such registration to our shareholders and the board is in full agreement with the decision.”
NXRA Competitors
| Company | Last | Change |
| Johnson and Johnson | $62.31 USD | +0.37 |
| Kao Corporation | ¥2,090 JPY | +60.00 |
| L'Oreal | €72.23 EUR | +0.27 |
| Pfizer Inc | $18.36 USD | +0.25 |
| Procter & Gamble Co | $61.80 USD | -0.35 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | NXRA | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 0.0x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
|
NXRA |
||
NXRA transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
